Lomustine and Intermediate Dose Cytarabine in Older Patients With AML
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
A multicenter randomized trial was performed comparing induction therapy (IC: Idarubicin and
Cytarabine, 5+7) to ICL (the same drugs plus lomustine (CCNU), 200mg\m2 orally at day 1).
Patients in complete remission (CR) were then randomized to receive either maintenance
therapy or intensification with intermediate-dose cytarabine and idarubicin followed by
maintenance therapy.